Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Subscribe Search Contacts Login 
  • Users Online: 412
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2018  |  Volume : 30  |  Issue : 3  |  Page : 253-256

Evaluation of the efficacy of carbamazepine and gabapentin in the management of trigeminal neuralgia: A clinical study


Department of Oral Medicine and Radiology, Genesis Institute of Dental Sciences and Research, Ferozepur, Punjab, India

Correspondence Address:
Dr. Bhawandeep Kaur
Department of Oral Medicine and Radiology, Genesis Institute of Dental Sciences and Research, Ferozepur, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jiaomr.jiaomr_75_18

Rights and Permissions

Background: Trigeminal neuralgia (TN) is a syndrome of unilateral, paroxysmal, stabbing facial pain, originating from the trigeminal nerve. Carbamazepine still remains as the gold standard drug in terms of efficacy in TN. Over the time, several other drugs are also used as alternatives for TN such as oxcarbazepine, baclofen, lamotrigine, levetiracetam, gabapentin, valproate, botulinum toxin A injection. Objective: To Evaluate the efficacy of Carbamazepine and Gabapentin in the management of Trigeminal Neuralgia. Materials and Methods: A total of 42 patients with a mean age of 52.78 years included in the study were randomly divided into two groups A and B and were given the tablets of carbamazepine in the dose range of 400mg to 1200 mg and gabapentin in the dose range of 600mg to 1800mg and recalled after 3rd day, 15th day, 1 month and 3 month period to evaluate the response to the drugs. The collected data was subjected to statistical analysis. Results: The therapeutic effectiveness of carbamazepine recorded as good response in 52.38% of patients of group A after 72 hours of recall while 28.57% patients had an average response and 19% patients had not relieved off pain attacks at the dose of 400mg of carbamazepine. The therapeutic effectiveness of gabapentin recorded as good response in 52.38% of group B patients after 72 hours of recall while 42.8% patients had an average response at the dose of 600mg of gabapentin. Conclusion: The study suggests that gabapentin can be effective as first or second line treatment of trigeminal neuralgia, even in cases resistant to traditional treatment modalities.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed334    
    Printed1    
    Emailed0    
    PDF Downloaded112    
    Comments [Add]    

Recommend this journal